- HOME
- >
- Corporate Guide
- >
- Business Outline
Takara Bio Group Business
Gene Therapy
*Here, CDMO (Contract Development and Manufacturing Organization) refers to provision of contract services for drug development and manufacturing, in all steps of the process from formulation to final manufacturing, for clients such as pharmaceutical companies. Takara Bio provides CDMO focused on regenerative medicine products such as gene therapy.
Reagents, Instruments, and CDMO Services
Takara Bio supports academic and corporate life sciences activities by offering reagents, instruments, and CDMO services.
Research Reagents and Scientific Instruments
Research Reagents
Scientific Instruments
Thermal Cycler Dice® Real Time System III
Takara Bio sells reagents and instruments under three unique brands: TaKaRa®, Clontech®, and Cellartis®. These brands meet a wide range of needs in the life sciences field throughout the world, from basic and cutting-edge research to industrial applications.
Product under the TaKaRa® brand are developed and sold by Takara Bio, and the brand offers an extensive lineup that covers all fields of bio research, including genetic, protein, and cellular engineering.
It got its start as the first brand in Japan to develop and market restriction enzymes, back in 1979. PCR systems (machines and reagents) were soon added to the product lineup as well. Over its more than 40 years of history, TaKaRa® has added more and more products, and provides powerful support to bio researchers. In 2020, we added in vitro diagnostics using PCR technology, further expanding our scope.
Our Clontech® brand was developed by the former Clontech Laboratories, Inc. (now Takara Bio USA, Inc.) and primarily offers products for advanced molecular biological research.
It has particularly strong product offerings for functional genomic analysis, protein interaction research, and DNA library construction. We are developing outstanding products for the rapidly expanding market of next-generation sequencers under this brand. In the area of scientific instruments, we are developing and marketing an ultralow input genetic analysis system for single-cell analysis.
Our Cellartis® brand is developed by a company formerly called Cellartis AB (now Takara Bio Europe AB) founded by members of the University of Gothenburg in Sweden. Its product lineup includes cell products such as ES and iPS cells, as well as products for advanced stem cell research such as products for cell culturing.
Offers a wide range of products for genetic engineering and all other kinds of biotechnology research applications.
Main products
- Genetic research reagents
- Genetic testing kits
- Genome analysis services
- Products related to novel coronavirus testing（including in vitro diagnostics）
Has a lineup of products optimized for advanced research in fields such as molecular and cell biology.
Main products
- Analytical reagents for next-generation sequencers
- Single-cell analysis systems
- Gene expression research reagents
- Fluorescent proteins series for gene function analysis
- Genome-editing research reagents
Offers iPS cell products and other products used in stem cell research, as well as contract services in the field.
Main products
- iPS cell research reagents
- Products for stem cell culturing and induction of differentiation
Click here for more Information
(Takara Bio USA website)
CDMO Services
Center for Gene and Cell Processing
Center for Gene and Cell Processing II
Through our CDMO business, Takara Bio provides contract services for biologics development and manufacturing, in all steps of the process from formulation to final manufacturing, for clients such as pharmaceutical companies. Our two top fields of focus are services related to regenerative medicine products such as gene therapy, and services related to genetic analysis and testing, such as genome sequencing and genetic analysis for regenerative medicine products.
At our Center for Gene and Cell Processing, which is the hub for our CDMO business, we are enhancing our capabilities for manufacturing and quality control testing for vectors and transduced cells. As we expand our facilities, we are urgently working to meet the growing demands from CDMO services by developing efficient expansion culture methods and technology to scale up vector production, as well as by automating manufacturing processes.
In vitro Diagnostics
Takara Bio develops, manufactures, and sells in vitro diagnostics(marketing approval in Japan) that detect viruses and others using a real time RT-PCR kit and an immunochromatographic assay.
SARS-CoV-2 Nucleic acid detection kit
SARS-CoV-2
Nucleic acid detection kit
We are selling kits that detect the RNAs of the novel coronavirus (SARS-CoV-2) using real time RT-PCR methods. A feature of this kit is that it eliminates the need for RNA purification by adopting a simplified extraction method, which reduces testing times compared to standard PCR testing methods. In addition, to detect internal control simultaneously, we can prevent false negative characterization due to PCR inhibition, which helps to assist in the diagnosis of the novel coronavirus infectious disease (COVID-19).
HEALGEN Rapid COVID-19 Antigen test
HEALGEN Rapid COVID-19 Antigen test
We are selling the “Rapid COVID-19 Antigen Test” that detect nucleocapsid protein antigen from the novel coronavirus. This test supplied with sterile swab, extraction tube with buffer and tip, and test cassette. After insertion of the swab into nostile (2 – 4 cm deep), roll the swab against the insides of the nostile. Insert the swab into the extraction tube, and mix well. Add drops of the solution into the sample well of the test cassette. The test reaction will take 15 minutes.
Gene Therapy Business
Takara Bio aims to maximize the value of its proprietary platform technology for biologics development and pursue practical applications for gene therapy.
New modality creation
Research image of gene therapy
We are preparing to apply for marketing authorization of NY-ESO-1 siTCR™ gene therapy utilizing siTCR™ technology in Japan. We are preparing to begin clinical trials of next-generation CAR gene therapy utilizing JAK/STAT technology in fiscal year ending Mar, 2023.
Developing platform technology for biologics development
We are putting effort into developing platform technology for biologics development in areas such as gene therapy.
● Establish methods for mass production of viral vectors such as AAVs
● Develop next-generation CAR gene therapy for solid cancers
● Develop viral vectors for new organ-specific in vivo gene therapies
● Develop next-generation TCR/CAR gene therapy with a persistent antitumor effect